Difference between revisions of "Ibritumomab tiuxetan (Zevalin)"
m (moved Ibritumomab (Zevalin) to Ibritumomab tiuxetan (Zevalin)) |
|
(No difference)
| |
Revision as of 21:51, 10 February 2012
General information
Class/mechanism: Anti-CD20 antibody chelated by tiuxetan to a radioactive agent (Y-90, yttrium-90; or In-111, indium-111). Y-90 emits beta radiation, which causes cellular damage via free radicals. This results in damage to cells which express the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35).[1][2]
Route: IV
Extravasation: potential vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)[3]
- Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)[4]